Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)
Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)
Tenggara, Jeffry Beta (26028154300); Rachman, Andhika (15056701600); Prihartono, Joedo (6602605635); Rachmadi, Lisnawati (55062422000); Panigoro, Sonar Soni (56790104300); Heriyanto, Didik Setyo (54420130300); Sutandyo, Noorwati (26028099200); Nasution, Intan Russianna (58856886500); Rahadiati, Familia Bella (57222312428); Steven, Ricci (58808727700); Betsy, Rachelle (58035832700); Juanputra, Samuel (58035300800); Sudoyo, Aru Wisaksono (6507478291)
The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study
2024
BMC Research Notes
17
1
44
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183752630&doi=10.1186%2fs13104-024-06704-z&partnerID=40&md5=de027f325777bb9ecbe793095eb9ae40
Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No. 71, RW.5, Kec. Senen, Central Jakarta, Jakarta, 10430, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, MRCCC Siloam Hospital Jakarta, Jakarta, Indonesia; Department of Community Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomical Pathology, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Surgical Oncology, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomical Pathology, Dr. Sardjito Hospital–Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital, Jakarta, Indonesia; Division of Hematology and Medical Oncology, Gatot Soebroto Army Hospital Jakarta, Jakarta, Indonesia; Department of Anatomical Pathology, Gatot Soebroto Army Hospital Jakarta, Jakarta, Indonesia; Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Background: Triple-negative breast cancer (TNBC) has been documented as the most aggressive subtype of breast cancer. This study aimed to analyze antitumor and protumor immune activities, and their ratios as significant prognostic biomarkers in metastatic TNBC (mTNBC). Methods: A multicenter cohort study was conducted among 103 de novo mTNBC patients. The expression of CD8 and CD163 was evaluated using immunohistochemistry staining, CD4 and FOXP3 using double-staining immunohistochemistry, and PD-L1 using immunohistochemistry and RT-PCR. Results: Multivariate analysis revealed that high CD4/FOXP3 (HR 1.857; 95% CI 1.049–3.288; p = 0.034) and the CD8/CD163 ratio (HR 2.089; 95% CI 1.174–3.717; p = 0.012) yield significantly improved 1 year overall survival (OS). Kaplan–Meier analysis showed that high levels of CD4 (p = 0.023), CD8 (p = 0.043), CD4/FOXP3 (p = 0.016), CD8/FOXP3 (p = 0.005), CD8/CD163 (p = 0.005) ratios were significantly associated with higher rate of 1 year OS. Furthermore, 1 year OS was directly correlated with antitumor CD4 (R = 0.233; p = 0.018) and CD8 (R = 0.219; p = 0.026) and was indirectly correlated with protumor CD163 and FOXP3 through CD4/FOXP3 (R = 0.282; p = 0.006), CD4/CD163 (R = 0.239; p = 0.015), CD8/FOXP3 (R = 0.260; p = 0.008), and CD8/CD163 (R = 0.258; p = 0.009). Conclusion: This is the first study to demonstrate that high levels of CD4/FOXP3 and CD8/CD163 significantly improved the 1 year OS in de novo mTNBC patients. Thus, we recommend the application of these markers as prognosis determination and individual treatment decision. © 2024, The Author(s).
B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cohort Studies; Forkhead Transcription Factors; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Triple Negative Breast Neoplasms; forkhead transcription factor; FOXP3 protein, human; programmed death 1 ligand 1; CD8+ T lymphocyte; clinical trial; cohort analysis; genetics; human; metabolism; multicenter study; neoadjuvant therapy; pathology; triple negative breast cancer; tumor associated leukocyte
Department of Anatomical Pathology; Department of Internal Medicine, University of Utah; Department of Radiology, Weill Cornell Medical College
The authors gratefully acknowledged all staff of the medical record, the Department of Radiology, the Department of Hematology and Medical Oncology, the Department of Anatomical Pathology (Deny Suprihatin), and the Clinical Epidemiology Division, Department of Internal Medicine (Utami Susilowati).
BioMed Central Ltd
17560500
38308298
Article
Q2
534
9718